Greenwood Capital Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Greenwood Capital Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,655	Closed	-$551K	–	213
2018 Q4	$551K	Buy	5,655 +1,180	+26%	+$139K	0.14%	90
2018 Q3	$622K	Buy	+4,475	New	+$561K	0.14%	91
2017 Q1	–	Sell	-1,653	Closed	-$202K	–	224
2016 Q4	$202K	Buy	+1,653	New	+$202K	0.06%	177
2014 Q2	–	Sell	-14,530	Closed	-$2.21M	–	158
2014 Q1	$2.21M	Sell	14,530 -17,325	-54%	-$2.75M	0.71%	68
2013 Q4	$4.23M	Buy	31,855 +11,884	+60%	+$1.43M	1.31%	25
2013 Q3	$2.32M	Buy	+19,971	New	+$2.19M	0.82%	53

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Greenwood Capital Associates's ALXN Position: Q1 2019 in Review

Greenwood Capital Associates sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 5,655 shares — an estimated $551K sold.

Greenwood Capital Associates first reported a position in ALXN in Q3 2013 and held it in 6 quarters. The position peaked at $4.23M in Q4 2013. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Greenwood Capital Associates reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Greenwood Capital Associates sold 5,655 Alexion Pharmaceuticals shares in Q1 2019, an estimated $551K.
Greenwood Capital Associates first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Greenwood Capital Associates's Alexion Pharmaceuticals position peaked at $4.23M in Q4 2013.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Greenwood Capital Associates's 13F filing for Q1 2019, filed 3 May 2019.